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a b s t r a c t
INTRODUCTION: Aggressive ﬁbromatosis or Desmoid ﬁbromatosis is a benign tumor which originated
form mesenchymal tissues of the body. This tumor has strong potential of recurrence and inﬁltration but
it does not metastasize to other organs of the body. This case series is focused to determine the treatment
outcomes for pediatric patients of aggressive ﬁbromatosis.
METHODOLOGY: It is a retrospective case series conducted on 7 patients presented to section of Orthopedics, department of surgery of our institute in Karachi. We included all the cases of pediatric patients
from 1 to 16 years, with biopsy proven ﬁbromatosis from January 2000 to December 2015.
PRESENTATION OF CASES: Out of 7 pediatric patients, there were 6 (85.7%) males and 1 (14.3%) female
patient. The median age was 6 years IQR (5–11) years. Gluteal region was the most common site of
disease. Four patients (57.1%) had positive tumor margins while three (42.9%) had negative margins. Out
of 7 patients, 4 patients (57.1%) had recurrent disease and they had positive margins. The median Disease
Free survival time was 14 months and there was no expiry of patients.
CONCLUSION & RECOMMENDATION: The conclusion of our study was that aggressive ﬁbromatosis is more
prevalent in children below 15 years of age and disease burden is higher in male gender. Positive margins
after surgery indicate a high risk for disease recurrence therefore; primary surgery with negative margins
is the treatment of choice for children with AF. However, we recommend that multicenter trials should
be conducted in the future to clarify the role of adjuvant treatment for patients with pediatric AF.
© 2018 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction
Desmoid tumor or aggressive ﬁbromatosis (AF) is a benign
tumor of borderline malignant condition, it is inﬁltrative,
deep-seated and muscoloapo neurotic in nature. World health
organization (WHO) deﬁnes ﬁbromatosis as a tumor that originates
from mesenchymal tissues which is non-metastatic but presented
as locally belligerent lesion which accounts for 0.03% of neoplasms
and 3% of every type of soft tissue lesion. Although it is nonmetastasizing tumor but it has high frequency of recurrence [1]. The
incidence rate of AF per year is 0.2–0.4 per 100,000 populations and
there are two peaks of incidence among children falling in age group
of 6 years – 15 years and from age of puberty to 40 years of age in
females. It is a locally destructive tumor that arises from connective
tissue, muscoloaponeurotic and fascial muscle sheath that undergoes ﬁbroblastic proliferation. AF has a very high predisposition for
local recurrence [2,3].
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In children, the mean age for diagnosis of AF is 8 years with age
range 0–19 years and majority are boys. However, it is observed that
the incidence of AF is much higher in children with positive family
history of aggressive ﬁbromatosis, Gardner’s syndrome and adenomatous polyposis. Children present with slow growing, painless
mass. Although the pathogenesis of these tumors is ambiguous but
an important factor that may be responsible for its occurrence could
be the deregulation of beta-catenin pathway in which the tumor
suppressor gene is responsible for maintaining the beta-catenin
levels which in turn changes the nuclear signaling and translation
of its pathway [4].
Records of 7 patients were retrieved from January 2000 to
December 2015, presented to section of Orthopedics, department
of surgery of our institute in Karachi. We included all the pediatric patients ranging 1–6 years, with biopsy proven ﬁbromatosis.
Patients of other border line benign /malignant conditions were
excluded. Since the data of the patients was retrieved via records
therefore Ethical exemption was taken from the ethics review committee of our institute. The aim of this study is to analyze the long
term outcomes of seven cases of pediatric ﬁbromatosis presenting
to a tertiary care hospital in Karachi, Pakistan.

https://doi.org/10.1016/j.ijscr.2018.09.032
2210-2612/© 2018 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).
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Table 1
Demographic and clinical characteristics of pediatric ﬁbromatosis patients.
Factors
Age (years)
Median (IQR)
Gender
Male
Female
Site of tumor
Gluteal region
Distal forearm
Axilla
knee
Margin status
Positive
Negative
Recurrence
Yes
No

n(%)
6 (5-11)
6 (85.7)
1 (14.3)
4 (57.1)
1 (14.3)
1 (14.3)
1 (14.3)
4 (57.1)
3(42.9)
4 (57.1)
3(42.9)

months and 71 months. The median Disease Free survival time
was 14 months. All patients were alive on last follow up, completing 15 years of survival; only one patient was lost to follow
up. Moreover, 6 (85.7%) patients received no adjuvant therapy.
Only 1 patient who had multiple recurrence had, received radiation
therapy on the third recurrence in other country. Other patients
with recurrence did not receive any adjuvant therapy because in
our country, the radiation oncologists are not having unanimous
opinion on this. Only negative surgical margins are main treatment plan. All the patients underwent wide margin excision after
preoperative incisional biopsy for diagnosis. Figs. 2 & 3 shows preoperative (incisional) biopsy and post-operative excisional biopsy
respectively. The research work has been reported in line with the
PROCESS criteria [5].

3. Discussion

Fig. 1. MRI pelvis of ﬁbromatosis of right gluteal region.
Coronal plane showing mass inﬁltrating in the adjacent gluteus muscles and entering in pelvis.
Axial plane showing no lymphadenopathy and normal vessels.

2. Case series
Out of 7 pediatric patients, there were 6 (85.7%) males and 1
(14.3%) female patient. The median age was 6 years IQR (1–16)
years. The most common site of AF was gluteal region, 4 (57.1%),
followed by distal forearm 1(14.3%), axilla 1 (14.3%), knee 1 (14.3%).
All of the patients had a common clinical presentation of swelling
in the lesion affected site for at least 3 months and only 2 patients
had pain symptoms. Patients were advised MRI and X –ray in radiological imaging. The MRI pelvis of one of the patient diagnosed with
ﬁbromatosis of right gluteal region showed the mass lesion inﬁltrates into the adjacent gluteus muscles and enter into the pelvis
through the sciatic foramen. It is indenting the urinary bladder and
rectum, however the fat planes appear to be preserved. No signiﬁcant pelvic lymphadenopathy noted and the visualized vessels
showed normal ﬂow voids (Fig. 1a & b).
4(57.1%) of the children had positive tumor margins while
3 (42.9%) had negative tumor margins. Recurrence of disease
occurred in 4 (57.1%) patients, while 3 (42.9%) had no recurrence (Table 1). Out of the 4 patients that had recurrent disease,
3 patients had recurrence at 28 months, 34 months and 14 months
respectively while one patient had 3 recurrences at 23 months, 35

Our study replicated the ﬁndings of several other studies
regarding AF in the pediatric population. The median age of the
participants of study was 6 years which was consistent with the
ﬁndings from other studies that indicates that ﬁbromatosis can
affect any age group but it is more evident among children. However, it is reported that about 25% of all AFs occur among children
of less than 15 years of age [6]. The possible explanation of this can
be that the histo-morphology and biological behavior of AFs among
children is more aggressive as compared to adults due to the high
cellularity of the tumor [6].
This study results also indicate that majority of the children who
had aggressive ﬁbromatosis (AF) were boys. Literature also suggest that AF is higher among males [7]. Although there is dearth
of information regarding the biology of AF, but literature suggests that targeting endocrine-mediated proliferation and other
signaling pathways has yielded development of treatments with
some clinical efﬁcacy. It is also observed that anti-estrogen therapy exhibits anti-proliferative activity in such tumors. Hormonal
therapies such as tamoxifen, toremifene, megestrol, progesterone,
testolactone, and goserelin have shown improvement with the
prognosis of such tumors [4]. Hence, the possible explanation of
males been affected by this tumor as shown in our study and literature may be due to the involvement of some hormonal factors.
However this needs further to exploration through large scale studies specially among pediatric population.
Majority of the patients in our study had tumor located in the
gluteal region followed by the extremities. Literature also indicates that majority of these tumors occur at extremities followed
by abdominal, thoracic and rarely in the head and neck [8].

M. Umer et al. / International Journal of Surgery Case Reports 52 (2018) 45–48

47

Fig. 2. Pre-operative (incisional) biopsy.
[A] Low power view of the lesion exhibiting fascicles of spindle cells against ﬁbrotic background. (H&E stain; 100x magniﬁcation) [B] High power view of spindle cells with
bland, elongated and vesicular nuclei. (H&E stain; 400× magniﬁcation) [C] Spindle cells showing patchy expression for alpha smooth muscle actin and [D] patchy nuclear
expression for ␤-Catenin IHC stains. (400× magniﬁcation).

Fig. 3. Post-operative (excisional) biopsy.
[A] Low power view of the lesion exhibiting fascicles of spindle cells against ﬁbrotic background. (H&E stain; 100× magniﬁcation) [B] High power view of spindle cells with
bland, elongated and vesicular nuclei. (H&E stain; 400× magniﬁcation) [C] Entrapped atrophic skeletal muscle ﬁbers (short arrows) and lymphoid aggregate (large arrow).
(H&E stain; 200× magniﬁcation) [D] Entrapped adipose tissue (lshort arrow). (H&E stain; 200× magniﬁcation).
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Additionally, our study results also suggested that after surgery
a high number of individuals had positive tumor margin and all of
them had recurrence of disease. A study indicated a higher proportion of children who had positive margins after primary surgery
developed disease recurrences versus those with negative margins
[7]. Therefore, the high risk of disease recurrence among patients
with positive margins indicates that there is a need of exploration
of the role of the adjuvant treatment in such patients. A study conducted in Netherland on a sample of 13 children suggested that
younger children (0–18 years) who received radiotherapy showed
less locoregional control of disease however, when the dose was
increased above 55 Gy, there was an improvement in the outcome
but on the contrary the complications were increased. On the contrary in our country, the concept of adjuvant treatment is still
ambiguous and post radiation therapy complications could be a
reason. Moreover, studies also suggest that the recurrence rate in
children varies from 23%–83% which results in multiple resections.
Furthermore, studies also suggests that negative surgical margins
causes decrease in the recurrence of AF [4,7,8].
The overall survival status of our study patients is 100% at 15
years, there is no death reported for the patients who were on follow up and this survival pattern is comparable to the survival status
reported in literature [8]. All of the patients in our study were in
regular follow up with us.
Patients in our study had recurrence and majority of the patients
had not received any adjuvant therapy except one patient who
had multiple recurrences. Literature suggests that adjuvant therapy
must be considered for patients with residual disease and among
those who have recurrent, progressive, or unresectable tumor.
Traditional cytotoxic and non-cytotoxic agents are the chemotherapeutic therapy of choice [9]. However, there is still a need of
multicenter, prospective (randomized) trials to clarify the role of
adjuvant treatment for patients with pediatric AF [3].
4. Conclusions and recommendations
The conclusion of our study is that AF is commonly found among
children below 15 years of age, affecting males more as compared to
females. Positive margins after surgery indicate a high risk for disease recurrence therefore; primary surgery with negative margins
is the treatment choice for children with AF. However, radiation
may assist in maintaining local control of these tumors in patients
with positive margins or residual disease therefore use of adjuvant
therapy in children with AF may be a reasonable alternative. However, multicenter prospective (randomized) trials will be necessary
to clarify the role of adjuvant treatment for patients with pediatric
AF.
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